The survival of patients with metastatic melanoma has improved with treatment with BRAF and MEK inhibitors [1] or with immunotherapy such as anti-PD-1 or anti-CTLA-4 antibodies [2, 3]. This evidence concerns the gene BRAF and metastatic melanoma.